Retinal vascular occlusion in patients having hyperhomocysteinemia is a known entity. However its treatment still controversial especially after organ transplantation. The objective of this work is to report a case of retinal vein thrombosis in kidney transplanted patient and discuss the management of this case by B vitaminotherpy and bevacizumab. A 47 year old Moroccan patient flowed for unknown end stage kidney disease on hemodialysis from september 2005 have been transplanted by the kidney of his wife on july 2013. After five months the patient presented with a great decrease of visibility related to retinal venous thrombosis and all explorations were negative except hyperhomocysteinemia. Firstly we decided to start B vitaminoterpy and oral folic acid for three months with decrease the Hcy serum level but without improving clinical status. Thus, we prescribe intraocular bevacizumab (dose) every thre weeks conducting to a spectacular evolution. However there was a treatment dependence and patient still on the same treatment. The management of this situation still unknown but we conclude that B vitaminotherapy is not effective leading us to use intraocular anti VEGF. The use of bevacizumab was effective to improve visibility of our patient whereas dependence and cost of treatment. Our result still an only observational case and prospective randomized studies are necessary to prove effectiveness of this treatment and help us to make decision easier.